Brief: Oncolytics Biotech Advances Toward Registration-Enabling Trial For Pelareorep In Breast Cancer With Submission Of Type C Meeting Request To FDA
11/04/2024 12:11
April 11 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® ADVANCES TOWARD REGISTRATION-ENABLING
TRIAL
FOR PELAREOREP IN BREAST CANCER WITH SUBMISSION OF TYPE C
MEETING REQUEST TO FDA
Source text for Eikon: ID:nPn65P4Dja
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer